A Step Forward in the Fight Against Dementia-Are We There Yet?
作者信息
Wolk David A, Rabinovici Gil D, Dickerson Bradford C
机构信息
Penn Alzheimer's Disease Research Center, Perelman School of Medicine, Department of Neurology, University of Pennsylvania, Philadelphia.
Weill Institute for Neurosciences, Memory and Aging Center, Alzheimer's Disease Research Center, Department of Neurology, University of California, San Francisco, San Francisco.
出版信息
JAMA Neurol. 2023 May 1;80(5):429-430. doi: 10.1001/jamaneurol.2023.0123.
Abstract
摘要
相似文献
1
A Step Forward in the Fight Against Dementia-Are We There Yet?对抗痴呆症的征程又迈进了一步——我们实现目标了吗？
JAMA Neurol. 2023 May 1;80(5):429-430. doi: 10.1001/jamaneurol.2023.0123.
2
Lecanemab: Looking Before We Leap.仑卡奈单抗：三思而后行。
Neurology. 2023 Oct 10;101(15):661-665. doi: 10.1212/WNL.0000000000207505. Epub 2023 Jul 21.
3
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.抗淀粉样蛋白单克隆抗体莱卡奈单抗：16项警示说明。
J Alzheimers Dis. 2023;94(2):497-507. doi: 10.3233/JAD-230099.
4
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.利斯的明透皮贴剂（Leqembi）并不适合阿尔茨海默病患者。
Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379.
5
Profiling lecanemab as a treatment option for Alzheimer's disease.剖析 Lecanemab 作为阿尔茨海默病的治疗选择。
Expert Rev Neurother. 2024 May;24(5):433-441. doi: 10.1080/14737175.2024.2333970. Epub 2024 Apr 3.
6
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.Lecanemab Clarity AD：早期阿尔茨海默病的一项随机、双盲 3 期临床试验的生活质量结果。
J Prev Alzheimers Dis. 2023;10(4):771-777. doi: 10.14283/jpad.2023.123.
7
Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial.用于早期阿尔茨海默病患者的 Lecanemab：一项 2b 期剂量发现随机临床试验的贝叶斯分析。
JAMA Netw Open. 2023 Apr 3;6(4):e237230. doi: 10.1001/jamanetworkopen.2023.7230.
8
A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.改善阿尔茨海默病护理的途径：从CLARITY AD试验模拟lecanemab在早期阿尔茨海默病中的长期健康结局
Neurol Ther. 2023 Jun;12(3):863-881. doi: 10.1007/s40120-023-00473-w. Epub 2023 Apr 2.
9
Piecing together the Alzheimer's puzzle: Lecanemab's role in treatment.拼凑阿尔茨海默病之谜：lecanemab在治疗中的作用。
Neurodegener Dis Manag. 2023 Oct;13(5):257-259. doi: 10.2217/nmt-2023-0026. Epub 2023 Dec 12.
10
Lecanemab and APOE Genotyping in Clinical Practice-Navigating Uncharted Terrain.临床实践中的lecanemab与APOE基因分型——探索未知领域
JAMA Neurol. 2023 May 1;80(5):431-432. doi: 10.1001/jamaneurol.2023.0207.
引用本文的文献
1
Measuring time saved in Alzheimer's disease: What is a meaningful slowing of progression?衡量阿尔茨海默病中节省的时间：有意义的疾病进展减缓是怎样的？
Alzheimers Dement (N Y). 2025 Apr 11;11(2):e70081. doi: 10.1002/trc2.70081. eCollection 2025 Apr-Jun.
2
Navigating barriers to dementia specialty care among vulnerable populations: Insight from a multidiscipline care navigation team.应对弱势群体中痴呆症专科护理的障碍：来自多学科护理导航团队的见解。
J Alzheimers Dis Rep. 2025 Jan 31;9:25424823241308456. doi: 10.1177/25424823241308456. eCollection 2025 Jan-Dec.
3
Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy.边缘叶为主的年龄相关性TDP-43脑病的临床标准。
Alzheimers Dement. 2025 Jan;21(1):e14202. doi: 10.1002/alz.14202. Epub 2025 Jan 14.
4
Perceptions about dementia clinical trials among underrepresented populations: a nationally representative survey of U.S. dementia caregivers.代表性不足人群对痴呆症临床试验的看法：一项针对美国痴呆症照顾者的全国代表性调查。
Alzheimers Res Ther. 2024 Oct 15;16(1):224. doi: 10.1186/s13195-024-01579-5.
5
Perceptions about dementia clinical trials among underrepresented populations: A nationally representative survey of U.S. dementia caregivers.未充分代表人群对痴呆症临床试验的看法：一项对美国痴呆症护理人员的全国代表性调查。
Res Sq. 2024 Jun 14:rs.3.rs-4492550. doi: 10.21203/rs.3.rs-4492550/v1.
6
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's Disease.早期阿尔茨海默病中抗淀粉样蛋白单克隆抗体治疗的管理框架。
CNS Drugs. 2024 Jul;38(7):493-505. doi: 10.1007/s40263-024-01097-w. Epub 2024 Jun 5.
7
Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease.进展分析与传统方法定量阿尔茨海默病疾病进展减缓的比较。
Alzheimers Res Ther. 2024 Feb 29;16(1):48. doi: 10.1186/s13195-024-01413-y.
8
Feasibility of Identifying Factors Related to Alzheimer's Disease and Related Dementia in Real-World Data.在真实世界数据中识别与阿尔茨海默病及相关痴呆症相关因素的可行性
medRxiv. 2024 Feb 13:2024.02.10.24302621. doi: 10.1101/2024.02.10.24302621.
9
The search for clarity regarding "clinically meaningful outcomes" in Alzheimer disease clinical trials: CLARITY-AD and Beyond.探寻阿尔茨海默病临床试验中“有临床意义的结局”的清晰度：CLARITY-AD 及以后。
Alzheimers Res Ther. 2024 Feb 16;16(1):37. doi: 10.1186/s13195-024-01412-z.
10
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.在早期阿尔茨海默病中，接受 LeCanemab 和 Elenbecestat 的 2 期和 3 期安慰剂对照、双盲、随机临床试验中，美国不同种族和民族参与者的入组率。
Ann Neurol. 2024 Feb;95(2):288-298. doi: 10.1002/ana.26819. Epub 2023 Oct 25.
本文引用的文献
1
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.一名接受lecanemab治疗并因中风接受t-PA治疗的患者发生多处脑出血。
N Engl J Med. 2023 Feb 2;388(5):478-479. doi: 10.1056/NEJMc2215148. Epub 2023 Jan 4.
2
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
3
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
4
Donanemab in Early Alzheimer's Disease.多奈单抗用于早期阿尔茨海默病
N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13.
5
Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies.归因于年龄相关神经病理学的阿尔茨海默病痴呆的可归因风险。
Ann Neurol. 2019 Jan;85(1):114-124. doi: 10.1002/ana.25380. Epub 2018 Dec 19.
6
Cerebral Amyloid Angiopathy: Diagnosis, Clinical Implications, and Management Strategies in Atrial Fibrillation.脑淀粉样血管病：心房颤动的诊断、临床意义和管理策略。
J Am Coll Cardiol. 2017 Aug 29;70(9):1173-1182. doi: 10.1016/j.jacc.2017.07.724.
7
Impact of multiple pathologies on the threshold for clinically overt dementia.多种病变对临床显性痴呆阈值的影响。
Acta Neuropathol. 2017 Aug;134(2):171-186. doi: 10.1007/s00401-017-1717-7. Epub 2017 May 9.
Zotero 插件